摘要
目的 :研究阿魏酸钠对家兔心室肌复极及有效不应期 (ERP)的影响 ,探讨其抗心律失常的可能机制。方法 :16只家兔随机分为阿魏酸钠组与胺碘酮组 ,各组同步记录体表心电图 (ECG)及右室心内膜单相动作电位 (MAP) ,比较在窦性心律下 ,用药前及用药后窦性心动周长 (SCL)、QRS时限 (QRSD)、MAP振幅 (MAPA)、ERP及复极 90 %时程 (MAPD90 )的变化。结果 :阿魏酸钠发挥与胺碘酮一致的时间依赖性延长MAPD90 与ERP作用 ,但不改变ERP/MAPD90 比值 ,胺碘酮用药 15min ,ERP及MAPD90 分别由用药前的 (12 5 .0 0± 16 .2 6 )ms、(14 3.12± 15 .80 )ms延长为 (199.0 0± 2 1.6 2 )ms、(2 16 .88± 2 3.14 )ms(P <0 .0 1) ;阿魏酸钠用药 2 5min ,ERP及MAPD90 分别由用药前的 (12 2 .5 0± 8.13)ms、(14 0 .0 0± 6 .2 5 )ms延长为 (14 3.75± 6 .87)ms、(16 4 .38± 7.19)ms(P <0 .0 1)。结论 :经与胺碘酮比较 ,推测阿魏酸钠具有Ⅲ类抗心律失常药物的抗心律失常特性。
Objective:The acute effects of sodium ferulate on the prolongation of ventricular repolarization and refractoriness were investigated in rabbit's right ventricular myocardium in order to study its antiarrhythmic mechanism in vivo. Method:Sixteen rabbits were randomly divided into two groups: the sodium ferulate and the amiodarone group. Suface electrocardiogram and the monophasic action potential (MAP) of right ventricular endocardium were simultaneously recorded before and after intravenous administration. The sinus cycle length (SCL), amplitude of MAP(MAPA), the duration of QRS, MAP at 90%(QRSD, MAPD 90 ) and effect refractory period (ERP) were evaluated. Result:Sodium ferulate caused significantly time dependent prolongation of the ERP and MAPD 90 but did not change the ratio of ERP to MAPD 90 just like amidarone. After 15 minutes administration of amiodarone, the ERP and MAPD 90 were prolonged from ( 125.00 ± 16.26 )ms and ( 143.12 ± 15.80 )ms to ( 199.00 ± 21.62 ) and ( 216.88 ± 23.14 )ms respectively(P< 0.01 ). Similarly, after 25 minutes administration of soduim ferulate, the ERP and MAPD 90 were prolonged from ( 122.50 ± 8.13 )ms, ( 140.00 ± 6.25 )ms to ( 143.75 ± 6.87 )ms and ( 164.38 ± 7.19 ) ms respectively (P< 0.01 ).Conclusion:Sodium ferulate is a potassium channel blocker with characteristic of class Ⅲ antiarrhythmic agents just like amidarone.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2002年第5期226-228,共3页
Journal of Clinical Cardiology
关键词
动作电位
阿魏酸钠
抗心律失常药
Action potential
Sodium ferulate
Anti arrhythmia agents